Research
Search
Close
GUO Minggao
- Chief Physician, Graduate Supervisor
- Department: General Surgery
- Research Area: Surgery (General Surgery)
- Research Interests: Thyroid disease diagnosis and treatment
- Contact: guominggao203@163.com
- Fellowship, Department of General Surgery, Shanghai Sixth People's Hospital, 2005
- PhD from Naval Medical University, 2003
- MD from Naval Medical University, 2000
- BD from Xuzhou Medical University, 1991
- Chief Physician, Department of General Surgery, Shanghai Sixth People's Hospital
- Li MF, Zhang R, Guo MG, Li LX, Lu HK, Lu JX, Jia WP. FAM172A protein promotes the proliferation of human papillary thyroid carcinoma cells via the p38 mitogen-activated protein kinase pathway. Mol Med Rep. 2016 Jan;13(1):353-8. doi: 10.3892/mmr.2015.4548.
- Xu PP, Zeng S, Xia XT, Ye ZH, Li MF, Chen MY, Xia T, Xu JJ, Jiao Q, Liu L, Li LX, Guo MG. FAM172A promotes follicular thyroid carcinogenesis and may be a marker of FTC. Endocr Relat Cancer. 2020 Nov;27(11):657-669. doi: 10.1530/ERC-20-0181
- Ye Z, Zeng S, Xu P, Liu W, Wang S, Xia X, Su C, Guo M. The Strategy of Conditionally Replicating Adenovirus-Mediated PreS2 Mini-Antibody Expression Has Dual Effects of Inhibiting HBV Infection and Preventing Hepatocellular Carcinoma. Cancer Manag Res. 2021 Feb 24;13:1869-1876. doi: 10.2147/CMAR.S298331
- Liu W, Wang S, Ye Z, Xu P, Xia X, Guo M. Prediction of lung metastases in thyroid cancer using machine learning based on SEER database. Cancer Med. 2022 Jun;11(12):2503-2515. doi: 10.1002/cam4.4617
- Xu P, Xia X, Yang Z, Tian Y, Di J, Guo M. Silencing of TCTN1 inhibits proliferation, induces cell cycle arrest and apoptosis in human thyroid cancer. Exp Ther Med. 2017 Oct;14(4):3720-3726. doi: 10.3892/etm.2017.4940
- 01/08/2014-01/09/2017
Science and Technology Commission of Shanghai Municipality Project, ¥200000, 14411964100
FAM172A protein as a serum marker for papillary thyroid carcinoma
Bed application research
Role: Project leader - 01/01/2017-12/31/2020
National Natural Science Foundation of China (Key Program), ¥570000, 81672373
Directed expression of PreS2 microantibody therapy strategy for HBV-associated liver cancer
Prevention and control effect
Role: Project leader
